Characterization of the effects on pruritus by novel treatments for atopic dermatitis.
Journal
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
ISSN: 1610-0387
Titre abrégé: J Dtsch Dermatol Ges
Pays: Germany
ID NLM: 101164708
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
07
05
2021
accepted:
26
10
2021
pubmed:
28
12
2021
medline:
4
3
2022
entrez:
27
12
2021
Statut:
ppublish
Résumé
Chronic pruritus is a common and debilitating symptom in patients with atopic dermatitis and contributes to impairment of quality of life. Effective treatment of pruritus should therefore be one of the main treatment goals in patients with atopic dermatitis. Pathophysiologically, the histamine-independent pruritogens interleukin-31, interleukin-13, and interleukin-4, have been shown to play a major role in atopic dermatitis. All three cytokines can mediate chronic pruritus via Janus kinase 1/2 signaling pathways. Novel drugs target these pathways and have shown rapid and sustained reduction of pruritus in patients with atopic dermatitis in clinical use and in phase II and III clinical trials. Here we summarize the published data on the effects of these drugs on itch parameters such as overall reduction in pruritus intensity and percent of patients with atopic dermatitis achieving a relevant reduction in itch. Each of the novel drugs shows very good effects on pruritus. These data offer hope for an even better and possibly more specific treatment of pruritus in patients with atopic dermatitis in the future. In addition, the different pharmacological approaches give us the chance to learn more about the pathophysiology of pruritus in atopic dermatitis.
Substances chimiques
Cytokines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
150-156Informations de copyright
© 2021 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.
Références
Cassano N, Tessari G, Vena GA, Girolomoni G. Chronic pruritus in the absence of specific skin disease: an update on pathophysiology, diagnosis, and therapy. Am J Clin Dermatol 2010; 11(6): 399-411.
Metz M. Are we facing a change in the treatment of chronic pruritus? Br J Dermatol 2019; 181(5): 877-8.
Ansorge C, Miocic JM, von Bubnoff D, Technau-Hafsi K. Dermatological conditions presenting to the emergency dermatological unit of a university hospital in Germany. J Dtsch Dermatol Ges 2018; 16(12): 1451-6.
Hawro T, Przybylowicz K, Spindler M et al. The characteristics and impact of pruritus in adult dermatology patients: A prospective, cross-sectional study. J Am Acad Dermatol 2021; 84(3): 691-700.
Huet F, Faffa MS, Poizeau F et al. Characteristics of pruritus in relation to self-assessed severity of atopic dermatitis. Acta Derm Venereol 2019; 99(3): 279-83.
Kage P, Simon JC, Treudler R. Atopic dermatitis and psychosocial comorbidities. J Dtsch Dermatol Ges 2020; 18(2): 93-102.
Ständer S. Atopic Dermatitis. N Engl J Med 2021; 384(12): 1136-43.
Bieber T. Novel therapies based on the pathophysiology of atopic dermatitis. J Dtsch Dermatol Ges 2019; 17(11): 1150-62.
Dillon SR, Sprecher C, Hammond A et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 2004; 5(7): 752-60.
Zheng T, Oh MH, Oh SY et al. Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J Invest Dermatol 2009; 129(3): 742-51.
Zhang Q, Putheti P, Zhou Q et al. Structures and biological functions of IL-31 and IL-31 receptors. Cytokine Growth Factor Rev 2008; 19(5-6): 347-56.
McCormick SM, Heller NM. Commentary: IL-4 and IL-13 receptors and signaling. Cytokine 2015; 75(1): 38-50.
Ranasinghe C, Trivedi S, Wijesundara DK, Jackson RJ. IL-4 and IL-13 receptors: Roles in immunity and powerful vaccine adjuvants. Cytokine Growth Factor Rev 2014; 25(4): 437-42.
Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet 2020; 396(10247): 345-60.
Chovatiya R, Lei D, Ahmed A et al. Clinical phenotyping of atopic dermatitis using combined itch and lesional severity: A prospective observational study. Ann Allergy Asthma Immunol 2021; 127(1): 83-90e2.
Silverberg JI, Yosipovitch G, Simpson EL et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. J Am Acad Dermatol 2020; 82(6): 1328-36.
Guttman-Yassky E, Blauvelt A, Eichenfield LF et al. Efficacy and Safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol 2020; 156(4): 411-20.
Wollenberg A, Blauvelt A, Guttman-Yassky E et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 2021; 184(3): 437-49.
Silverberg JI, Toth D, Bieber T et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol 2021; 184(3): 450-63.
Kabashima K, Matsumura T, Komazaki H et al. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med 2020; 383(2): 141-50.
Nezamololama N, Fieldhouse K, Metzger K, Gooderham M. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib. Drugs Context 2020; 9: 8-5.
Simpson EL, Lacour JP, Spelman L et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 2020; 183(2): 242-55.
Reich K, Kabashima K, Peris K et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2020; 156(12): 1333-43.
Simpson EL, Sinclair R, Forman S et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet 2020; 396(10246): 255-66.
Bieber T, Simpson EL, Silverberg JI et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med 2021; 384(12): 1101-12.
Guttman-Yassky E, Teixeira HD, Simpson EL et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet 2021; 397(10290): 2151-68.
Reich K, Teixeira HD, de Bruin-Weller M et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2021; 397(10290): 2169-81.
Blauvelt A, Teixeira HD, Simpson EL et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2021; 157(9): 1047-55.
Kobyletzki LB, Thomas KS, Schmitt J et al. What factors are important to patients when assessing treatment response: an international cross-sectional survey. Acta Derm Venereol 2017; 97(1): 86-90.
Jo CE, Gooderham M, Beecker J. TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors. Int J Dermatol 2021 Apr 30. [Epub ahead of print].
Paller AS, Stein Gold L, Soung J et al. Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis. J Am Acad Dermatol 2021; 84(3): 632-8.